Welcome to our dedicated page for Lifemd news (Ticker: LFMD), a resource for investors and traders seeking the latest updates and insights on Lifemd stock.
LifeMD, Inc. provides virtual primary care through a direct-to-patient telehealth platform that combines telemedicine, laboratory access, pharmacy services, a 50-state affiliated medical group, an affiliated pharmacy and a U.S.-based patient care center. Company news commonly covers its Telehealth operating segment, recurring subscription revenue, patient sign-ups, gross margin trends and guidance.
Recurring updates also address LifeMD’s specialized care areas, including primary care, men’s and women’s health, weight management and hormone therapy. News items feature GLP-1 weight management offerings such as Wegovy and Foundayo, branded therapy access through manufacturer programs, preferred stock dividends, executive leadership changes and investor conference participation.
LifeMD (NASDAQ: LFMD), a virtual healthcare services provider, has announced key leadership appointments. Shayna Webb Dray, previously Senior VP of Operations, has been promoted to Chief Operating Officer. Webb Dray, who joined LifeMD in 2021, brings over 15 years of operations and supply chain experience.
The company also expanded Jessica Friedeman's role to Chief Marketing and Product Officer and promoted Jacob Ellison to Chief Analytics Officer, where he will lead data strategy and AI innovation. These appointments aim to strengthen LifeMD's operational excellence and support its expansion into new healthcare verticals.
LifeMD (Nasdaq: LFMD), a leading virtual primary care provider, has scheduled its second quarter 2025 financial results announcement for August 5, 2025, after market close. The company will host a conference call at 4:30 p.m. Eastern time.
LifeMD operates through a vertically integrated platform featuring a 50-state affiliated medical group, a 22,500-square-foot pharmacy, and a U.S.-based patient care center. The company provides telemedicine services, laboratory and pharmacy access, and specialized treatment for over 200 medical conditions, including primary care, men's and women's health, weight management, and hormone therapy.
Medifast (NYSE: MED), the company behind the OPTAVIA® health and wellness program, has scheduled its Q2 2025 financial results announcement for August 4, 2025, after market close.
The company will host a conference call at 4:30 p.m. ET featuring Chairman and CEO Dan Chard and CFO Jim Maloney. The call will be available via webcast on Medifast's Investor Relations website and will remain archived through November 3, 2025. Telephone participants can dial (201) 389-0879, with playback access available through August 11, 2025.
LifeMD (Nasdaq: LFMD), a virtual primary care services provider, has announced a quarterly dividend payment for holders of its 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP). The company will distribute a cash dividend of $0.5546875 per share. The dividend is payable on July 15, 2025, to shareholders of record as of July 3, 2025.
LifeMD (NASDAQ: LFMD) has partnered with Novo Nordisk to launch a limited-time $299 introductory bundle for self-pay patients prescribed Wegovy®. The bundle includes Wegovy® at $199 and LifeMD's virtual weight management program, available until June 30, 2025. After the first month, the program will cost $599 monthly with no long-term commitment required.
The collaboration strengthens LifeMD's ability to deliver FDA-approved GLP-1 medications through an integrated care experience, targeting patients seeking alternatives to compounded therapies. LifeMD's platform provides comprehensive services from virtual consultation to prescription fulfillment and ongoing support. Wegovy® is available through NovoCare® Pharmacy integration for eligible uninsured patients or those whose insurance doesn't cover weight-loss medications.
LifeMD (NASDAQ: LFMD), a virtual primary care services provider, has announced its participation in three major investor conferences in May 2025:
- H.C. Wainwright BioConnect Conference on May 20 at Nasdaq, New York City
- B. Riley Securities Conference on May 21-22 at the Ritz-Carlton, Marina Del Rey, featuring a corporate overview presentation
- Craig-Hallum Conference on May 28 at The Depot Renaissance Minneapolis Hotel
Management will conduct one-on-one meetings with investors at all events, with additional small group meetings at the Craig-Hallum conference.
LifeMD has announced plans to expand access to Wegovy® (semaglutide) through NovoCare® Pharmacy for cash-pay patients. The company will offer the FDA-approved weight loss medication at a reduced self-pay cost of $499 per month, including home delivery.
Through their virtual care platform, LifeMD provides a comprehensive weight management program featuring:
- Virtual consultations
- Lab testing
- Diet and lifestyle support
- Prescriptions for anti-obesity medications including GLP-1s
The integration with NovoCare® Pharmacy allows direct access to all FDA-approved dose strengths of Wegovy®, which is notably the first GLP-1 therapy approved in the United States for both chronic weight management and cardiovascular risk reduction in adults with obesity. The service targets uninsured patients or those whose insurance doesn't cover prescription weight-loss medications.
LifeMD (Nasdaq: LFMD), a virtual primary care services provider, has scheduled its Q1 2025 financial results announcement for May 6, 2025, after U.S. market close.
The company will host a conference call and webcast at 4:30 p.m. Eastern time to discuss the results for the three months ended March 31, 2025. Interested parties can join through multiple channels:
- Toll-Free: 800-225-9448
- International: 203-518-9708
- Conference ID: LIFEMD
A live webcast will be available, and an archived version will be accessible for replay after the event.